Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
europe top stories
3
×
fda
3
×
life sciences
national blog main
new york top stories
europe blog main
indiana blog main
indiana top stories
national
national top stories
new york blog main
san francisco top stories
arena pharmaceuticals
billy dunn
biogen
boehringer ingelheim
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
cardiovascular disease
colorectal cancer
detroit blog main
detroit top stories
drug prices
drug pricing
eisai
eli lilly
empagliflozin
europe
evrysdi
gene therapy
genentech
ionis pharmaceuticals
lorcaserin
lung cancer
novartis
What
drug
3
×
fda
patients
3
×
medicine
approval
approved
atrophy
bid
boehringer
cancer
daily
diabetes
eisai
eli
evrysdi
expand
fallen
flags
friday
green
higher
home
incidence
ingelheim
intended
lights
lilly
liquid
lorcaserin
loss
market
marketed
marketing
medicine’s
muscular
new
oral
post
pulls
rejects
Language
unset
Current search:
drug
×
patients
×
" europe top stories "
×
fda
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks